ALD518 News
Most Popular ALD518 Story
Alder bags $1B RA licensing deal for lead drug
Alder Biopharmaceuticals has scored a $1.07 billion licensing deal with Bristol-Myers Squibb for its IL-6 inhibitor for rheumatoid arthritis, ALD518. Under the deal Alder gets $85 million upfront, up Read more...
Latest Headlines
- November 10, 2009
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
